Table 1.
Patient characteristics (N = 51)
| N | % | |
|---|---|---|
| Median age (range), years | 66 (41–82) | |
| Sex | ||
| Male | 29 | 56.9 |
| Female | 22 | 43.1 |
| ECOG PS | ||
| PS = 0 | 42 | 82.4 |
| PS = 1 | 9 | 17.6 |
| Site of primary tumor | ||
| Colon | 31 | 60.8 |
| Rectum | 18 | 35.3 |
| Cecum | 2 | 3.9 |
| Histology of primary tumor | ||
| Well differentiated adenocarcinoma | 11 | 21.6 |
| Moderately differentiated adenocarcinoma | 33 | 64.7 |
| Poorly differentiated adenocarcinoma | 3 | 5.9 |
| Others | 4 | 7.8 |
| Metastatic sites | ||
| Liver limited | 13 | 25.5 |
| Other single region | 9 | 17.6 |
| Multiple site | 29 | 56.9 |
| UGT1A1 status | ||
| Wild | 11 | 21.6 |
| *6 Polymorphism | 7 | 13.7 |
| *28 Polymorphism | 4 | 7.8 |
| Compound heterozygote | 0 | 0 |
| Unmeasured | 15 | 29.4 |
| Previous therapy | ||
| Previous therapy with panitumumab or cetuximab | 16 | 31.4 |
| Previous therapy with bevacizumab | 31 | 60.8 |
ECOG Eastern Cooperative Oncology Group, PS performance status